Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. A. Anastasakis
Dr. C. Kotsiopoulou
Dr. C. Ritsatos
Two brothers (patient A & patient B) with a morphological severe form of hypertrophic cardiomyopathy (HCM) and early onset are presented. Their mother died suddenly at the age of 28 years (see Pedigree). Post-mortem macroscopic analysis revealed HCM.
Patient A was diagnosed with hypertrophic obstructive cardiomyopathy (HOCM) at the age of 9 months based on echocardiography measurements. The electrocardiogram (ECG) recorded left ventricular hypertrophy (LVH) voltage, repolarization disorders, short P-R interval and preexitation sign. Laboratory investigations showed increased plasma transaminases and creatine kinase (CK) levels. At the age of 14 years, he experienced a syncopal episode. His Holter monitoring revealed burst of non-sustained ventricular tachycardia (NSVT) and his LVWmax reached 30 mm. Electrophysiological study (EPS) provoked ventricular tachycardia (VT). An automatic cardioverter defribillator (ICD) was implanted and five discharges occurred during the following year. The evolution of HCM to the dilated hypokinetic form (end stage disease) was very fast. The patient died at the age of 17 years due to pump failure, while waiting heart transplantation (Figure 1).Patient B, 5 years older than patient A, was diagnosed with HCM (non obstructive form) at the age of 9 years. Ten years later he experienced palpitation and a syncopal episode. Increased liver enzymes and CK plasma levels were observed. The ECG recorded bradycardia with repolarization changes, LVH by voltage and episodes of Mobitz I and II. His left ventricular function started gradually to deteriorate and at the same time bursts of NSVT were recorded in his 24h Holter monitoring. An ICD was implanted and one discharge was recorded. His condition gradually evolved to the dilated form. At the age of 22 years, he underwent successful heart transplantation (Figure 2).Points to consider:The two brothers’ final diagnosis of HCM substrate was clarified following further evaluation. The National Transplantation committee was initially reluctant to approve the heart transplantation. Finally, the permission was given and patient B is still alive and well 12 years after the transplantation.
Answers and results:• PRKAG2 gene related HCM disease• Danon disease• Mitochondrial disease
Which tests do you recommend for further evaluation of those two patients? 1. A skeletal muscular biopsy to search for vacuolar myopathy, and if it is present, to analyse the biopsy immunohistochemically with specific LAMP2 antibodies. 2. Direct molecular screening of the LAMP2 gene should be performed to confirm Danon’s disease.
To distinguish sarcomeric HCM from Danon’s disease is important, as the pathophysiology, clinical evolution, prognosis, mode of inheritance, and therefore genetic counselling are very differentAs a first step, all patients with HCM should be considered, whatever the familial context, except when it is a familial form with a male to male transmission (which excludes X linked disease). All of these patients should benefit from careful clinical and biological evaluation, including clinical muscular testing and determination of serum CK concentration, to search for additional features of Danon’s disease. Interestingly skeletal myopathy is mild in most cases (85%) but all male patients had increased serum CK concentration. Wolff-Parkinson-White syndrome was present in 35%, mild mental retardation was observed in 70%, and most patients had HCM and low ejection fraction. Women were less severely affected, with later onset cardiomyopathy. As a second step, Danon’s disease can be reasonably excluded when HCM is isolated (without associated abnormalities). In contrast, in the presence of unusual clinical associations (especially HCM and clinical skeletal myopathy), the diagnosis of Danon’s disease should be discussed further. Other hereditary cardiac diseases should also be discussed (such as mitochondrial disease, glycogen storage disorders, and PRKAG2 gene related disease) because of overlapping clinical features (especially skeletal muscle disease and pre exitation syndrome). As a third step, a skeletal muscular biopsy to search for vacuolar myopathy, and if it is present, to analyse the biopsy immunohistochemically with specific LAMP2 antibodies. Finally direct molecular screening of the LAMP2 gene should be performed to confirm or exclude Danon’s disease. However, molecular genetic screening is less invasive, possibly more efficient or sensitive (if mutations do not lead to a stop codon and the absence of the protein), and remains the criterion of reference in women (where the protein may be present because of one normal X chromosome).
OUR CASE Skeletal muscle biopsy of patient B showed autophagic vacuoles and complete absence of LAMP2 protein (fig. 1). Molecular analysis in both patients revealed a mutation, a point deletion, c.716delT in exon 5, of the LAMP2 gene , setting the diagnosis of Danon disease (fig. 2) Patient B also showed reduced plasma a-galactosidase activity with no features of Fabry’s disease. Mutation analysis of the alpha-galactosidase A gene, revealed a substitution already described, c.937G>T, which is however believed to be a non-disease-causing variant. The causative mutation, c.716delT in exon 5, was reconfirmed in his brother’s DNA (pts A)who died while waiting for heart transplantation and also was found in his mother’s DNA (died suddenly – see pedigree) which was extracted from the paraffin blocks.
Figure 1.Lack of LAMP 2 immunostaining in muscle biopsiesFigure 2. LAMP2 mutation (c.716delT)Patient B also showed reduced plasma a-galactosidase activity with no features of Fabry’s disease. Mutation analysis of the alpha-galactosidase A gene, revealed a substitution already described, c.937G>T, which is however believed to be a non-disease-causing variant. The causative mutation, c.716delT in exon 5, was reconfirmed in his brother’s DNA (pts A) who died while waiting for heart transplantation and also was found in his mother’s DNA (died suddenly – see pedigree) which was extracted from the paraffin blocks.
In conclusion, physicians must be aware of Danon’s disease, a disease with variable phenotypic expression, which may mimic HCM but results in a very different clinical evolution, prognosis, mode of inheritance, and subsequently different genetic counselling.Why the National Committee was reluctant to proceed to the heart transplantation?
Danon Cardiomyopathy is a multi-system disease. Mild peripheral muscle myopathy and elevated liver enzymes was the reason that members of the committee were reluctant to proceed to heart transplantation .In our case the patient 10 years after the heart transplantation is alive and well.
Presented by : C. Ritsatos , C. Kotsiopoulou , A. Anastasakis, Unit of inherited Cardiovascular Diseases1st Department of Cardiology, University of Athens, Hippokrateion Hospital